This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Sanofi saw risk of Maze's drug 'dislodging its own dominance,' US FTC complaint says

( December 11, 2023, 22:53 GMT | Official Statement) -- MLex Summary: Sanofi recognized that Maze Therapeutics' drug for Pompe disease risked "dislodging its own dominance," the US Federal Trade Commission said in a complaint to block an exclusive licensing deal between the companies filed in federal district court in Massachusetts. "Sanofi is now trying to buy out Maze rather than compete with it."See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections